PTC Therapeutics, Inc. Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent
PTC Therapeutics, Inc. (PTCT) reported Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent of 0.00% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent · last filed 2020-03-02
- PTC Therapeutics, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2019 was 0.00%.
- PTC Therapeutics, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2018 was 0.00%.
- PTC Therapeutics, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2017 was -0.26%, a 285.71% decline from fiscal 2016.
- PTC Therapeutics, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2016 was 0.14%.
| Period end | Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent 12 month |
|---|---|
| 2019-12-31 | 0.00% 10-K · filed 2020-03-02 |
| 2018-12-31 | 0.00% 10-K · filed 2020-03-02 |
| 2017-12-31 | -0.26% 10-K · filed 2020-03-02 |
| 2016-12-31 | 0.14% 10-K · filed 2019-03-01 |
| 2015-12-31 | 0.00% 10-K · filed 2018-03-06 |
| 2014-12-31 | 0.00% 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |